Clinical utility of emerging biomarkers in prostate cancer liquid biopsies

AbstractThe TERT promoter (pTERT) mutations, C228T and C250T, play a significant role in malignant transformation by telomerase activation, oncogenesis and immortalisation of cells. C228T and C250T are emerging as important biomarkers in many cancers including glioblastoma multiforme (GBM), where the prevalence of these mutations is as high as 80%. Additionally, the rs2853669 single nucleotide polymorphism (SNP) may cooperate with these pTERT mutations in modulating progression and overall survival in GBM. Using liquid biopsies, pTERT mutations, C228T and C250T, and other clinically relevant biomarkers can be easily detected with high precision and sensitivity, facilitating longitudinal analysis throughout therapy and aid in cancer patient management.In this review, we explore the potential for pTERT mutation analysis, via liquid biopsy, for its potential use in personalised cancer therapy. We evaluate the relationship between pTERT mutations and other biomarkers as well as their potential clinical utility in early detection, prognostication, monitoring of cancer progress, with the main focus being on brain cancer.

Download Full-text

Quantitative and Qualitative Analysis of Blood-based Liquid Biopsies to Inform Clinical Decision-making in Prostate Cancer

European Urology ◽

10.1016/j.eururo.2020.12.037 ◽

2021 ◽

Author(s):

Irene Casanova-Salas ◽

Alejandro Athie ◽

Paul C. Boutros ◽

Marzia Del Re ◽

David T. Miyamoto ◽

...

Keyword(s):

Prostate Cancer ◽

Decision Making ◽

Qualitative Analysis ◽

Clinical Decision Making ◽

Clinical Decision ◽

Liquid Biopsies

Download Full-text

The Clinical Utility of 18F-Fluciclovine PET/CT in Biochemically Recurrent Prostate Cancer: an Academic Center Experience Post FDA Approval

Molecular Imaging and Biology ◽

10.1007/s11307-021-01583-3 ◽

2021 ◽

Author(s):

Ryusuke Nakamoto ◽

Caitlyn Harrison ◽

Hong Song ◽

Kip E. Guja ◽

Negin Hatami ◽

...

Keyword(s):

Prostate Cancer ◽

Clinical Utility ◽

Recurrent Prostate Cancer ◽

Academic Center ◽

Fda Approval ◽

Pet Ct

Download Full-text

Towards Routine Implementation of Liquid Biopsies in Cancer Management: It Is Always Too Early, until Suddenly It Is Too Late

Diagnostics ◽

10.3390/diagnostics11010103 ◽

2021 ◽

Vol 11 (1) ◽

pp. 103

Author(s):

Maarten J. IJzerman ◽

Jasper de Boer ◽

Arun Azad ◽

Koen Degeling ◽

Joel Geoghegan ◽

...

Keyword(s):

Clinical Utility ◽

Clinical Laboratory ◽

Genomic Analysis ◽

Current Evidence ◽

Liquid Biopsies ◽

Blood Draw ◽

Minimum Quality Standards ◽

Cancer Management ◽

Alternative Funding ◽

And Performance

Blood-based liquid biopsies are considered a new and promising diagnostic and monitoring tool for cancer. As liquid biopsies only require a blood draw, they are non-invasive, potentially more rapid and assumed to be a less costly alternative to genomic analysis of tissue biopsies. A multi-disciplinary workshop (n = 98 registrations) was organized to discuss routine implementation of liquid biopsies in cancer management. Real-time polls were used to engage with experts’ about the current evidence of clinical utility and the barriers to implementation of liquid biopsies. Clinical, laboratory and health economics presentations were given to illustrate the opportunities and current levels of evidence, followed by three moderated break-out sessions to discuss applications. The workshop concluded that tumor-informed assays using next-generation sequencing (NGS) or PCR-based genotyping assays will most likely provide better clinical utility than tumor-agnostic assays, yet at a higher cost. For routine application, it will be essential to determine clinical utility, to define the minimum quality standards and performance of testing platforms and to ensure their use is integrated into current clinical workflows including how they complement tissue biopsies and imaging. Early health economic models may help identifying the most viable application of liquid biopsies. Alternative funding models for the translation of complex molecular diagnostics, such as liquid biopsies, may also be explored if clinical utility has been demonstrated and when their use is recommended in multi-disciplinary consensus guidelines.

Download Full-text